ArticleBMC complementary medicine and therapies2026
Chemical profiling and evaluation of in vitro antibacterial and antibiotic synergistic activities of Cleistanthus bracteosus Jabl. from Malaysian rainforests.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlants are rich and valuable sources of phytochemical constituents that can contribute to a variety of biological activities. The research in discovering novel antimicrobial compounds from plants has been of increased interest due to the global rise of antibiotic resistance. The present study aims to evaluate the in vitro antibacterial, antibiotic synergistic potential and the chemical profile of plant extracts associated with Cleistanthus bracteosus Jabl. found in Malaysian rainforests for the first time.
methodsThe antibacterial activity and synergistic antibacterial activity of chloroform, methanol and n-hexane crude extracts of C. bracteosus were determined against bacterial pathogens of Escherichia coli, Bacillus subtilis, Staphylococcus aureus, B. cereus, Pseudomonas aeruginosa, Salmonella typhi and Acinetobacter baumannii. The chloroform extracts were subjected to fractionation, chemical profiling, and field emission scanning electron microscopic (FE-SEM) analysis.
resultsThe chloroform stem extract exhibited the highest antibacterial activity which indicated a mean inhibition zone diameter (IZD) of 10 ± 0.26 mm against the Gram-positive bacterium B. cereus. The best synergistic activity was shown for chloroform wood extract when combined with ampicillin against A. baumannii, with a growth inhibitory index (GIIs) of 1.33. Potassium clavulanate actively synergised with chloroform stem extract against E. coli ATCC 10536 (IZD = 27 ± 0.56 mm) and chloroform bark extract against S. typhi (IZD = 28 ± 0.54 mm). C. bracteosus extracts showed the presence of secondary metabolites like flavonoids, phenols, tannins, alkaloids, coumarins, saponins and traces of terpenoids, with chloroform extracts of bark, stem and wood consisting of 20 bioactive phytochemical compounds according to gas chromatography-mass spectrometry analysis (GC-MS). Further analysis with high-performance liquid chromatography (HPLC) implied the presence of digoxigenin and lauric acid. The FE-SEM observations further elucidated the effects of C. bracteosus chloroform extracts on the morphology of susceptible organisms.
conclusionThe findings of this investigation justify that chloroform extracts of C. bracteosus can function as a novel antibacterial agent with synergistic potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.